Background-The purpose of this study was to evaluate the long-term safety of the Igaki-Tamai stent, the first-in-human fully biodegradable coronary stent made of poly-l-lactic acid. Methods and Results-Between September 1998 and April 2000, 50 patients with 63 lesions were treated electively with 84 Igaki-Tamai stents. Overall clinical follow-up (Ͼ10 years) of major adverse cardiac events and rates of scaffold thrombosis was analyzed together with the results of angiography and intravascular ultrasound. Major adverse cardiac events included all-cause death, nonfatal myocardial infarction, and target lesion revascularization/target vessel revascularization. During the overall clinical follow-up period (121Ϯ17 months), 2 patients were lost to follow-up. There were 1 cardiac death, 6 noncardiac deaths, and 4 myocardial infarctions. Survival rates free of all-cause death, cardiac death, and major adverse cardiac events at 10 years were 87%, 98%, and 50%, respectively. The cumulative rates of target lesion revascularization (target vessel revascularization) were 16% (16%) at 1 year, 18% (22%) at 5 years, and 28% (38%) at 10 years. Two definite scaffold thromboses (1 subacute, 1 very late) were recorded. The latter case was related to a sirolimus-eluting stent, which was implanted for a lesion proximal to an Igaki-Tamai stent. From the analysis of intravascular ultrasound data, the stent struts mostly disappeared within 3 years. The external elastic membrane area and stent area did not change. Conclusion-Acceptable major adverse cardiac events and scaffold thrombosis rates without stent recoil and vessel remodeling suggested the long-term safety of the Igaki-Tamai stent. (Circulation. 2012;125:2343-2352.)
I n the 1990s, the biocompatibility of poly-l-lactic acid (PLLA) was controversial. Zidar et al 1 reported a minimal inflammatory reaction and minimal neointimal hyperplasia with the use of PLLA stents in canine femoral arteries. On the other hand, Van der Giessen et al 2 reported a marked inflammatory response after the implantation of 5 different polymer stents, including lactic acid, in a porcine coronary model. Finally, a decade ago, the concept of a biodegradable stent came to fruition as the first biodegradable stents were used in the clinical setting. Dr Keiji Igaki, an engineer, and Dr Hideo Tamai, an interventional cardiologist who passed away on February 10, 2009 , invented the first-in-human fully biodegradable stent (Igaki-Tamai stent) made of PLLA. 3 At that time, 50 patients were treated with Igaki-Tamai stents in Japan, and 15 patients were treated with these stents outside of Japan (Italy, Netherlands, Germany, and Korea).
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Despite the promising initial and 6-month results, 3 the arrival of drug-eluting stents diverted attention from biodegradable stents. Drug-eluting stents significantly reduced in-stent restenosis rates and target lesion revascularization (TLR) rates compared with bare metal stents. 4 However, safety issues with drug-eluting stents, especially very late stent thrombosis (VLST), have become an increasingly reported problem, [5] [6] [7] and recently, increasing attention has been paid to fully biodegradable coronary stents. So far, initial and midterm results are available for 2 biodegradable stents: the bioabsorbable magnesium (AMS) stent (BIOTRONIK, Berlin, Germany), 8 and the bioresorbable everolimus-eluting PLLA (BVS) scaffold (Abbott Vascular, Santa Clara, CA). 9, 10 Moreover, the Igaki-Tamai stent, sold under the trade name REMEDY, is now clinically available for peripheral artery disease in Europe. However, further work is required to determine the long-term safety of these stents. Before putting the biodegradable drug-eluting PLLA stent into routine clinical practice, we need to confirm that PLLA does not cause any critical adverse events during the whole process of biodegradation. The purpose of this study was to assess the long-term safety of Igaki-Tamai stents in human coronary arteries.
Methods

Study Design and Study Cohort
We undertook a single-arm, single-center, observational prospective study that enrolled 50 patients treated with 84 Igaki-Tamai stents. The patients were eligible if they had stable ischemic heart disease with a lesion that could be treated by implantation of the Igaki-Tamai stent. The study was approved by the hospital ethics committee of Shiga Medical Center for Adults. Written informed consent was obtained from all patients (according to the Helsinki Declaration). The indications for stent implantation were the prevention of restenosis in a de novo lesion, restenosis of a major coronary artery after plain balloon angioplasty, and suboptimal results after plain balloon angioplasty. All patients were selected electively. Exclusion criteria were acute coronary syndrome, lesions located in the left main trunk, and chronic total occlusion. In this study, we followed up this cohort for Ͼ10 years to assess the long-term safety of IgakiTamai stents.
Igaki-Tamai Stent
The Igaki-Tamai stent (Kyoto Medical Planning Co, Ltd, Kyoto, Japan) is the first fully biodegradable stent implanted in human coronary arteries (Figure 1 ). The properties of the stent have been described previously. 3 Briefly, the stent is composed of a non-drugeluting, high-molecular-weight PLLA monofilament (183 kDa) with a zigzag helical coil design. PLLA is a biodegradable, thermoplastic, aliphatic polyester that is degraded to lactic acid and finally metabolized to carbon dioxide and water. The stent strut thickness is 0.17 mm (0.007 in); its diameter is 3.0, 3.5, and 4.0 mm; and its length is 12 mm. The stent structures are not radiopaque, and each end of the stent has implanted radiopaque gold markers.
The stent was deployed with a balloon-expandable 5F covered sheath system through an 8F guiding catheter. The balloon inflation was performed through heated contrasts of 80°with 30-second inflation at 6 to 14 atm. The stent has a self-expanding capability, and dilatation continues until equilibrium is attained between the circumferential elastic resistance of the arterial wall and the dilating force of the PLLA stent.
Procedures
All patients received 10 000 U intravenous heparin at the beginning of the procedure. Before stents were implanted, the lesions were dilated by an optimally sized balloon or debulked by directional atherectomy or rotational atherectomy if needed. The stent size was decided by intravascular ultrasound (IVUS) studies, and multiple stentings were performed, depending on lesion length, to cover the entire lesion. The stent was deployed by balloon inflation. Postdilatation was performed if needed. All patients were required to receive aspirin (81 mg/d) for at least 6 months and ticlopidine (200 mg/d) for 1 month, which is the usual dose in Japan.
In-Hospital Results and Clinical Follow-Up
The baseline characteristics of patients and lesions and in-hospital outcomes were obtained by a review of the medical records, procedural reports, and coronary angiograms. Clinical follow-up data were obtained by either telephone interviews or reviews of medical records. The occurrence of major adverse cardiac events (MACEs) and definite/probable scaffold thrombosis was recorded. MACEs included cardiac death, noncardiac death, nonfatal myocardial infarction (MI), TLR, and target vessel revascularization (TVR).
Cardiac death included any death with a cardiac cause (eg, MI, congestive heart failure, low-output failure, fatal arrhythmia), unwitnessed death, and death of unknown cause. Noncardiac death included any death not covered by cardiac death. MI was defined as the presence of at least two of the following: ischemic symptoms, elevation in cardiac enzymes (creatine kinase and its MB isoenzyme) at least twice their upper normal limits, and new ECG changes compatible with MI. MI was classified as lesion-related MI and non-lesion-related MI by ECG and coronary angiography. Scaffold thrombosis (definite, probable, and possible) was defined according to Academic Research Consortium criteria. 11 Even if the implanted PLLA stent was considered completely biodegraded and thrombus was observed in the scaffolded lesion, it was considered scaffold thrombosis. TLR was defined as any repeat percutaneous coronary intervention of the target lesion or bypass graft surgery for restenosis or other complications. The target lesion was defined as the treated segment from 5 mm proximal to the stent to 5 mm distal to the stent. TVR was defined as any repeat percutaneous coronary intervention or coronary artery bypass graft surgery of the target vessel.
Quantitative Coronary Angiography and IVUS Analyses
Scheduled follow-up coronary angiography and IVUS were performed before, immediately after, 1 day after, and 6 months after the procedures. At the beginning of this study, we thought that the PLLA stent would have disappeared within 6 months. However, the PLLA stent did not disappear at 6 months of follow-up, and we recommended that all patients undergo angiography at 1 and/or 2 years of follow-up. After 2 years of follow-up, additional angiography and IVUS were performed on the basis of clinical indications as determined by the attending physicians.
Quantitative coronary angiography was analyzed with the Cardiovascular Measurement System (Medis Medical Imaging Systems, Leiden, the Netherlands). The procedure was considered successful if residual stenosis Ͻ50% with Thrombolysis in Myocardial Infarction grade 3 flow was achieved. Late loss was defined as the difference between minimal lumen diameter (MLD) after the procedure and at follow-up.
The IVUS system (CVIS, Boston Scientific Corp, Natick, MA) was used with an automated pullback at 0.5 mm/s. The image processing was performed by the echoPlaque software (INDEC Medical Systems, Santa Clara, CA). The external elastic membrane (EEM) area, the stent area, the minimal lumen area (MLA), and the projected MLD were measured. The EEM area and the stent area were measured every 1 mm, and the results were averaged. To assess the interobserver agreement, all IVUS images were measured by 2 observers, and the correlation coefficient for measurements between the 2 observers was 0.988 (PϽ0.001). To assess the intraobserver variability, 20 randomly selected IVUS images were remeasured, and the correlation coefficient for repeated measurements was 0.970 (PϽ0.001).
IVUS Echogenicity Analysis
Before quantitative IVUS echogenicity analysis was performed, the IVUS data were retrospectively ECG gated by the previously validated Intelligate method. [12] [13] [14] [15] Of note, a low frame rate does not allow accurate detection of near end-diastolic frames and cannot be processed by the Intelligate algorithm. Therefore, IVUS data acquired with a 30-MHz catheter and attached to a Clearview console were retrospectively corrected before further analyses. The postprocedural and follow-up IVUS images were analyzed side by side through a comparison of the matched segments, as previously described. 16 The lumen, scaffold, and EEM contours were detected with the CURAD Vessel Analysis software (Curad BV, Wijk bij Duurstede, the Netherlands), 17 and these contours were subsequently used to perform the echogenicity analysis.
Fully automated quantitative echogenicity analysis software, previously developed in house and validated, was used to quantify the hyperechogenicity changes in the scaffolded segment, as previously shown in the ABSORB trials. 18, 19 In brief, the mean gray value of the adventitia was used to classify tissue components as either hypoechogenic or hyperechogenic. The adventitia was defined as a layer extending from 0.2 to 0.5 mm outside the EEM. To avoid artifacts, tissue within acoustic shadowed areas was excluded and very high gray-level pixels were identified as upper tissue. 19 After the tissue identification process, the relative fraction of hypoechogenic versus hyperechogenic tissue volumes was calculated for the entire scaffolded segment. At the various follow-up time points, the echogenicity was calculated between the stent and the EEM contours as previously described. 18 The software calculated the echogenicity as a volume and percentage for each scaffolded segment (setting hypoechogenicity and hyperechogenicity to 100%).
Statistical Analysis
Continuous variables were expressed as meanϮSD. Paired comparisons of serial observations over time in the same lesions were performed by a Wilcoxon signed-rank test. Values of PϽ0.05 were considered significant. The time (days) to a MACE was calculated from the procedure date (If there were multiple procedure dates, the first was used). Kaplan-Meier life-table analysis was used to estimate cumulative event-free survival.
Results
Baseline Characteristics of Patients and Lesions
Between September 1998 and April 2000, 50 patients with 63 lesions were treated electively with 84 biodegradable IgakiTamai stents during 57 procedures at our institution. Baseline patient clinical characteristics are shown in Table 1 . Subjects included 44 men and 6 women with a mean age of 61Ϯ11 years. Lesion characteristics are shown in Table 2 . All target lesions were American Heart Association/American College of Cardiology type B or C. Debulking before stenting was performed in 16 procedures (2 rotational atherectomy and 14 directional atherectomy). All stents were successfully delivered, and angiographic success was achieved in all procedures.
In-Hospital Outcomes
There were no in-hospital MACEs except for 1 case of subacute scaffold thrombosis. This occurred in a patient who was taken off antiplatelet therapy secondary to an acute hemorrhagic gastric ulcer. Neither ticlopidine nor heparin was administered after gastric bleeding, and subacute scaffold thrombosis occurred on postoperative day 5. Although percutaneous coronary intervention was immediately performed, this patient suffered a nonfatal lesion-related MI.
Long-Term Clinical Outcomes
The mean clinical follow-up period was 121Ϯ17 months (maximum, 136 months), and the clinical follow-up rate was 100% at 4 years, 98% at 7 years, and 96% at 10 years. One patient was lost to follow-up at 4 years and 1 at 7 years. Kaplan-Meier event-free analysis of all-cause death, cardiac death, and MACEs is shown in Figure 2 . At the 10-year follow-up, 87% (95% confidence interval [CI], 77-97) of patients were free from all-cause death. Moreover, 98% (95% CI, 94 -100) of patients were free from cardiac death, and 50% (95% CI, 36 -64) of patients were free from MACEs. 
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All MACEs that occurred during the follow-up period are shown in Table 3 . One patient died of unknown causes at 57 months, and 6 other deaths were due to noncardiac causes. One lesionrelated MI and 2 non-lesion-related MIs were recorded.
The 10-year cumulative TLR and TVR rates are shown in Figure 3 . The cumulative rates of TLR per patient were 16% (95% CI, 6 -26) at both 1 and 3 years, 18% (95% CI, 7-29) at 5 years, and 28% (95% CI, 15-40) at 10 years. The cumulative rates of TVR per patient were 16% (95% CI, 6 -26) at both 1 and 3 years, 22% (95% CI, 11-33) at 5 years, and 38% (95% CI, 24 -52) at 10 years. There were 14 TLRs within 10 years, and the TLR rate was 33% (6 of 18) for lesions treated with multiple stenting and 18% (8 of 45) for lesions treated with single stenting.
According to Academic Research Consortium criteria, 1 case of definite very late scaffold thrombosis was recorded during the 10-year follow up period, which occurred in the same patient who had the previously mentioned lesion-related MI. This very late scaffold thrombosis occurred 10 years after implantation of Igaki-Tamai stents, but the patient also had a sirolimus-eluting stent (SES) implanted. Two Igaki-Tamai stents were implanted in the left anterior descending coronary artery in 1999. However, an SES was implanted in a new lesion just proximal to the Igaki-Tamai stents in 2006. In 2009, the patient was admitted to the hospital with acute coronary syndrome. The coronary angiogram of this case is shown in Figure 4 . It demonstrated a massive thrombus in the SES and a small amount of thrombus in the proximal portion of the lesion where the Igaki-Tamai stents had been implanted (ie, the thrombus was distributed mainly within the SES). After thrombus aspiration, IVUS images showed that the Igaki-Tamai stent struts had disappeared. Residual thrombus was observed in the SES, and additional balloon angioplasty was needed for this lesion. On the other hand, residual thrombus was not observed in the lesion where the IgakiTamai stent had been implanted, and additional balloon angioplasty was not needed for this lesion.
Antiplatelet Therapy
Although the scheduled duration of dual antiplatelet therapy (DAPT) was 1 month, the actual duration of DAPT was selected by the attending physicians. Of 50 patients, data were obtained in 48 patients on the prescription of DAPT in the first 3 years after PLLA implantation. The duration of DAPT was 1 month in 18 patients (36%), 2 to 3 months in 15 patients (30%), 4 to 12 months in 10 patients (20%), and 13 to 36 months in 5 patients (10%). Within 3 years after PLLA implantation, DAPT was restarted in 4 patients because of implantation of additional metallic stents or cerebral infarction.
Angiographic Results
Angiographic follow-up was performed 95% of the lesions at 6 months, 89% of the lesions at 1 year, 43% of the lesions at 5 years, and 20% of the lesions at 10 years. Changes in MLD and percent diameter stenosis of all available lesions except post-TLR lesions determined by quantitative coronary angiography are shown in Table 4 . In this unpaired comparison, the mean MLD decreased to 1.76Ϯ0.74 mm at 6 months, with improvement at 3 years. Serial changes in the MLD and percent diameter stenosis of 18 lesions without TLRs are also shown in Figure 5A . In these 18 lesions, angiography and IVUS were performed during the first 3 years. In this paired comparison, the mean MLD decreased to 2.08Ϯ0.63 mm at 6 months. After this time point, MLD improvement was observed, but the changes were not statistically significant (Pϭ0.12, 6 months versus 3 years).
IVUS Analysis
Quantitative IVUS analysis of all available lesions except post-TLR lesions is shown in Table 5 . In this unpaired comparison, the MLA decreased to 3.64Ϯ1.68 mm 2 at 6 months. However, after this time point, MLA improvement was observed. Serial changes in the cross-sectional areas of 
Nishio et al First-in-Human Biodegradable PLLA Coronary Stent
18 lesions without TLRs are also shown in Figure 5B . In this paired comparison, the MLA decreased to 4.23Ϯ1.82 mm 2 at 6 months. After this time point, MLA improvement was observed (Pϭ0.028, 6 months versus 3 years). The changes in the EEM and stent areas did not become significant until 3 years.
Serial IVUS findings of a representative case are shown in Figure 6A . Between poststenting and the 6-month follow-up, there were almost no changes in the number of stent struts. However, at 12 and 24 months, the number of the struts was decreased; finally, at 36 months, most of the struts had visually disappeared. After 36 months, we had the chance to see the IVUS images in a small number of patients (4 lesions at 42 months, 2 lesions at 48 months, and 3 lesions at 54 months). The stent struts of the Igaki-Tamai stent had also visually disappeared.
IVUS Echogenicity Analysis
The complete serial IVUS data (before, after, and at 6 months, 1 year, 2 years, and 3 years) on 13 lesions treated with a single stent and without TLR were analyzed for the echogenicity analysis. There was a significant increase in hyperechogenicity of the scaffolded segment after stent implantation (Pϭ0.018). A significant reduction in hyperechogenicity was detected beginning at 12 months, with a value of hyperechogenicity at 36 months comparable to the prestent implantation values ( Figure 6B ).
Histological Analysis
The stent strut was histologically examined in 1 case during the follow-up period. After 42 months of follow-up, directional atherectomy was performed to excise a lesion that was previously stented (Figure 7 ). Piecemeal fragments of artery wall were obtained. These specimens demonstrated intimal thickening composed of completed fibrosis with scant fibroblasts with few inflammatory cells. They also disclosed the remnants of polymeric struts. Around the remnants of polymeric struts, there was almost no inflammatory cell infiltration or foreign body reaction. Thrombus also was not observed. Alcian blue staining and periodic acid-Schiff staining are shown in Figure 7 . The space previously occupied by PLLA was stained by Alcian blue.
Discussion
The motivation for developing biodegradable stents has been to overcome the limitations of metallic stents. Metallic stents have a potential risk of stent thrombosis, can be an obstacle to surgical revascularization, and can be an impairment to noninvasive imaging such as multislice computed tomography. The development of stent malapposition in cases of plaque shrinkage/positive vessel remodeling can also occur. Currently, drug-eluting stents are the treatment of choice for coronary artery stenosis; however, VLST has become an important safety issue. Several mechanisms of VLST have been proposed, including delayed endothelialization, chronic inflammation of arteries, hypersensitivity reactions (eosinophilic infiltration), 20 and incomplete stent apposition with vessel remodeling. 21 All of these problems with metallic stents can be solved with the use of fully biodegradable stents because there are no foreign materials after PLLA degradation. Therefore, many cardiologists and engineers have recently focused their attentions on the development of a fully biodegradable stent.
In our study, there was a high survival rate free of cardiac death (98% at 10 years), demonstrating the long-term safety of this stent. During the 10 years of follow-up, only 1 cardiac death was recorded at 57 months. Although many noncardiac death cases were reported in this study, they have no relation to the Igaki-Tamai stents. MACE-free survival rates continued to decrease during follow-up (50% at 10 years), mainly as a result of the increase in TLR and TVR rates. During the process of biodegradation (1-3 years), TLR and TVR reached a near plateau, suggesting that the process of PLLA biodegradation does not correlate with increased risk of clinical events. There is the possibility that if the Igaki-Tamai stent becomes drug eluting, the TLR rates could be improved. At 5 years, the TLR rate was 18%, which is comparable to results of permanent bare metal stents. 22, 23 After 5 years, TLR rates progressively increased up to 28% at 10 years. This increase in TLR rates in this study during the long-term follow-up is difficult to evaluate, and there are few reports about long-term (5-10-year) clinical and angiographic outcomes. Kimura and colleagues 23 reported on the long-term (7-11 year) clinical and angiographic data of Palmaz-Schatz stents, and MACE-free rates continued to decrease during the follow-up period (37% at 8 years), which was similar to that of our study. Although late revascularization was due predominantly to progressive disease at nontarget sites, a significant decrease in MLD was observed from 6 months to late follow-up, and Kimura and colleagues concluded that progressive luminal narrowing beyond 4 years after coronary stent placement was common. Their findings are consistent with the increase in TLR/TVR rates in our study.
We have previously reported 14 cases that highlight the histological findings of new in-stent lesions developing beyond 5 years, 24 and in that study, new atherosclerotic progression occurred inside the metallic stent. This might also suggest that the new atherosclerotic progression was a possible cause of the increase in TLR rates after 5 years in our study.
Unpaired quantitative coronary angiography and quantitative analysis of IVUS showed that MLD and MLA decreased at 6 months, just as with metallic stents, with improvement at 3 years (Tables 4 and 5 ). This phenomenon was also observed in the paired analysis of 18 lesions without TLRs, but the improvement at 3 years was not statistically significant ( Figure 5 ). On the other hand, the stent area and EEM area did not change over time, suggesting that stent recoil and vessel remodeling did not occur during biodegradation. The absorption of the polymeric struts with plaque regression might contribute to the improvement of MLA over time.
In this cohort, the duration of DAPT was Ͻ3 months in 66% of patients. Two definite scaffold thrombosis cases were 
Nishio et al First-in-Human Biodegradable PLLA Coronary Stent
reported during the follow-up, but only 1 case was associated with the Igaki-Tamai stent. This patient had subacute scaffold thrombosis at day 5 that was due to cessation of antiplatelet therapy after acute hemorrhagic gastric ulcer. This was the first reported case of PLLA scaffold thrombosis in humans, which indicated that even though the stent material is not metallic, antiplatelet therapy is mandatory. The other case was that of a very late scaffold thrombosis at 10 years, which is explained entirely by VLST secondary to an SES. VLST might rarely occur after PLLA stent deployment because the struts disappear within 3 years, and stent thrombosis theoretically does not occur after strut degradation.
One major concern about PLLA stents has been whether stent degradation occurs in a reasonable time period. Previous bench work showed that degradation of polymers results in different acoustic properties of the material and that this process is detected by IVUS as diminishing gray-level intensities of the struts over time. 10, 18, 25 IVUS-derived quantitative echogenicity has previously been shown to be valuable in monitoring the degradation and bioresorption processes of polymeric scaffolds made of poly-lactide. 18 In the ABSORB trials testing the ABSORB BVS, which is made of polylactide, the quantitative differential echogenicity applied to monitor in vivo changes of the scaffold showed, for example, that at the expected time of total degradation and bioresorption (Ϸ2 years), the acoustic signals exhibited only little evidence of polymer residues. 10, 18 In the present analysis, the average hyperechogenicity significantly increased after stent implantation, compatible with the introduction of polymeric material in the coronary segment 26 ; a subsequent decrease was then detected up to 3 years, when the hyperechogenicity was close to that observed before the procedure ( Figure 6B) , suggesting that the Igaki-Tamai stent required 3 years to disappear from human coronary arteries. This finding may support a different degradation time between the Igaki-Tamai stent and the ABSORB BVS, which can be explained by the differences in the manufacturing process of the PLLA influencing the acoustic properties detected by the echogenicity analysis. 25 Of note, whereas the Igaki-Tamai stent consists totally of PLLA (molecular weight, 183 KDa), the BVS consists of PLLA (molecular weight is confidential) for the backbone and a copolymer of D-and L-lactic acid (PDLLA) for the coating, which includes everolimus. Because PDLLA has lower crystallinity than PLLA, PDLLA degrades faster than PLLA. 27 Although we only used the IVUS system in this study, other modalities such as optical coherence tomography may be useful for acquiring more information. Onuma and colleagues 28 reported optical coherence tomography images at 10-year follow-up of the Igaki-Tamai stent. The stent struts were not visible, and the endoluminal lining of the vessel was circular and smooth by optical coherence tomography in their study, which may further support the full degradation of the Igaki-Tamai stent.
Chronic inflammation, triggered by permanent polymers, may contribute to the increased risk of VLST and restenosis in drug-eluting stents. 20 Therefore, histological analysis of the PLLA stent struts in a chronic phase is of great significance, and we had the opportunity to examine the histology in 1 case ( Figure 7) . As mentioned previously, the remnants of polymeric struts were disclosed, complete endothelialization was observed, thrombus was not detected, and active inflammation was not observed around the strut remnants. Although the disappearance of PLLA could not be verified, Alcian blue staining on histological examination suggested that the strut remnants were filled with proteoglycan. These histological findings were compatible with the preclinical porcine studies of the ABSORB BVS. 10 There are still some deficits of this stent prototype that need to be improved, especially the system for stent deployment. In this initial cohort, we used contrast media heated to 80°to achieve adequate stent expansion, which might have affected the TLR rates. Moreover, because this stent has a self-expanding capability, a 5F covered sheath system was necessary. However, with the development of new technology, the Igaki-Tamai stent can now be implanted with normal contrast media. The cumbersome delivery system has also been improved. Currently, the Igaki-Tamai stent can be implanted in vitro through a 6F guiding catheter without a covered sheath system, but this catheter is not yet commercially available.
Our study has several limitations. This was an observational, single-center, nonrandomized study. There was no clinical events committee in this study; however, the data were analyzed independently from Dr Igaki, who had provided the Igaki-Tamai stents. The clinical follow-up period of 10 years was not planned at the beginning of this study, and late angiography and IVUS were not dictated by the protocol but rather were based on clinical indications. There were no independent core laboratories. Because of the small number of patients in our cohort, it is difficult to comment on events that have a low incidence, especially scaffold thrombosis. Because the significance level was not adjusted for multiple tests, the rates of type I error may be high. Angiography and IVUS follow-up studies were performed in a relatively small percent of patients, so there is the potential for bias.
Conclusions
Acceptable MACE rates similar to those of bare metal stents and scaffold thrombosis rates without stent recoil and vessel remodeling suggested the long-term safety of the Igaki-Tamai stent. In IVUS analysis, the stent struts mostly disappeared within 3 years. Although the mechanism of vessel healing in a chronic phase may not be the same between Igaki-Tamai stents and bioabsorbable drug-eluting PLLA stents, our study is essential in paving the way for a bioabsorbable drug-eluting PLLA stent, especially from the standpoint of long-term safety.
